{"schema_version":"secwatch.filing_event.v1","accession":"0001001233-25-000011","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.102500+00:00","generated_at":"2026-05-17T06:48:40.035855+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sangamo Therapeutics CFO Prathyusha Duraibabu resigns, effective Oct 1, 2025","bullets":["Duraibabu resigns to become senior leader at a private AI company; not due to any disagreement with Sangamo.","She will transition to part-time employment and remain interim principal financial officer until a successor is appointed.","Company thanks Duraibabu for contributions to strategic collaborations and investment allocations positioning Sangamo as a neurology-focused genomic medicines company."],"urls":{"canonical":"https://secwatch.observer/filing/0001001233-25-000011","json":"https://secwatch.observer/filing/0001001233-25-000011.json","markdown":"https://secwatch.observer/filing/0001001233-25-000011.md","text":"https://secwatch.observer/filing/0001001233-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000100123325000011/0001001233-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000100123325000011/sgmo-20250909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:48:40.035855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}